FGTI-2734 mesylate |
| Catalog No.GC39276 |
FGTI-2734 메실레이트는 FT 및 GGT에 대해 각각 250nM 및 520nM의 IC50을 갖는 RAS C-말단 모방 이중 파르네실 전이효소(FT) 및 게라닐게라닐 전이효소-1(GGT) 억제제입니다. FGTI-2734 메실레이트는 KRAS의 막 국소화를 방지할 수 있으므로 KRAS 내성 문제를 해결하고 돌연변이 KRAS 환자 유래 췌장 종양을 저지할 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2702297-24-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT, respectively. FGTI-2734 mesylate can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors[1].
[1]. Kazi A, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer Res. 2019 Jun 21.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *